Vikram E N T, Ilavarasan R, Kamaraj R
SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Kancheepuram (Dt.), Tamilnadu 603203, India.
Captain Srinivasa Murthy Central Ayurveda Research Institute, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Arumbakkam, Chennai, Tamilnadu 600106, India.
J Ayurveda Integr Med. 2022 Apr-Jun;13(2):100545. doi: 10.1016/j.jaim.2022.100545. Epub 2022 May 31.
Schedule E1 is an important part of Drugs and Cosmetics Act (Government of India) that comprises the list of poisonous drugs from plant, animal and mineral origins to be consumed under medical supervision. Ayurveda, the world's oldest medicinal system has a list of drugs represented in schedule E1 that are used since thousands of years. This review reports the anti-cancer activities of fifteen toxic ayurvedic drugs from plant origin represented in Drugs and Cosmetics Act, 1940. The information was collected from the various authentic sources, compiled and summarised. The plant extracts, formulations, phytoconstituents and other preparations of these drugs have shown effective activities against mammary carcinoma, neuroblastoma, non-small cell lung carcinoma, lymphocytic leukaemia, colorectal adenocarcinoma, Ehrlich ascites carcinoma, prostate adenocarcinoma, glioblastoma asterocytoma and other malignancies. They have various mechanisms of action including Bax upregulation, Bcl downregulation, induction of cell cycle arrest at S phase, G2/M phase, inhibition of vascular endothelial growth factors, inhibition of Akt/mTOR signalling etc. Certain traditional ayurvedic preparations containing these plants are reported beneficial and the possibilities of these drugs as the alternative and adjuvant therapeutic agents in the current cancer care have been discussed. The studies suggest that these drugs could be utilised in future for the critical care of malignancies.
附表E1是《药品和化妆品法案》（印度政府）的重要组成部分，其中包含需在医疗监督下使用的来自植物、动物和矿物来源的有毒药物清单。阿育吠陀是世界上最古老的医学体系，其有一些药物被列入附表E1，并且已经使用了数千年。本综述报告了1940年《药品和化妆品法案》中列出的15种源自植物的有毒阿育吠陀药物的抗癌活性。信息从各种可靠来源收集、汇编和总结。这些药物的植物提取物、制剂、植物成分和其他制剂已显示出对乳腺癌、神经母细胞瘤、非小细胞肺癌、淋巴细胞白血病、结肠腺癌、艾氏腹水癌、前列腺腺癌、胶质母细胞瘤星形细胞瘤和其他恶性肿瘤的有效活性。它们具有多种作用机制，包括上调Bax、下调Bcl、诱导细胞周期在S期、G2/M期停滞、抑制血管内皮生长因子、抑制Akt/mTOR信号传导等。据报道，某些含有这些植物的传统阿育吠陀制剂有益，并且已经讨论了这些药物作为当前癌症治疗中替代和辅助治疗剂的可能性。研究表明，这些药物未来可用于恶性肿瘤的重症护理。
